Table 3.
Univariate and multivariate prognostic analyses for overall survival.
| Univariate analyses | Multivariate analysis | ||||
|---|---|---|---|---|---|
| Parameters | N | HR (95% CI) | P value | HR (95% CI) | P value |
| Age at allogeneic HSCT | 147 | 1.03 (1.01–1.04) | 0.0005 | 1.28 (1.11–1.48) | 0.00089 |
| Age at RSV infection | |||||
| >25 years | 106 | 4.71 (1.88–11.85) | 0.001 | ||
| >40 years | 78 | 1.7 (0.97–2.98) | 0.064 | ||
| Allogeneic HSCT | |||||
| <6 months prior | 68 | 1.26 (0.73–2.16) | 0.40 | ||
| <1 month prior | 19 | 0.61 (0.24–1.55) | 0.30 | ||
| Sex (F) | 56 | 1.14 (0.66–1.97) | 0.64 | ||
| Lymphoproliferative disease | 35 | 1.58 (0.89–2.82) | 0.12 | ||
| Stem cell source | |||||
| Peripheral blood stem cells | 116 | 1.00 | |||
| Bone marrow | 15 | 0.58 (0.21–1.62) | 0.30 | ||
| Umbilical cord blood | 16 | 0.63 (0.25–1.58) | 0.32 | ||
| Myeloablative conditioning regimen | 59 | 0.44 (0.24–0.81) | 0.008 | ||
| Whole-body irradiation | 61 | 0.92 (0.53–1.59) | 0.77 | ||
| Antithymocyte globulina | 73 | 1 (0.58–1.7) | 0.99 | ||
| B cell depletionb | 14 | 1.71 (0.77–3.79) | 0.19 | ||
| Coinfection | 58 | 0.96 (0.5–1.67) | 0.90 | ||
| Viral | 38 | 0.9 (0.48–1.68) | 0.73 | ||
| Bacterial | 23 | 0.92 (0.43–1.95) | 0.82 | ||
| Site of infection | |||||
| LRTI | 1.00 | ||||
| URTI | 94 | 0.74 (0.43–1.27) | 0.28 | ||
| Nosocomial RSV infection | 11 | 0.21 (0.03–1.54) | 0.12 | ||
| Leukocytes > 2 × 109/l | 127 | 0.87 (0.41–1.84) | 0.71 | ||
| ALC > 0.5 × 109/l | 95 | 0.77 (0.44–1.33) | 0.34 | ||
| ALC ≤ 0.2 × 109/l | 21 | 0.78 (0.35–1.73) | 0.54 | ||
| ALC ≤ 0.1 × 109/l | 12 | 0.36 (0.1–1.25) | 0.11 | ||
| ANC > 0.5 × 109/l | 131 | 1.6 (0.58–4.45) | 0.37 | ||
| ANC ≤ 0.5 × 109/l | 16 | 0.62 (0.22–1.73) | 0.37 | ||
| Hypogammaglobulinemia ≤6.5g/l | 73 | 1.65 (0.96–2.86) | 0.072 | ||
| Hypogammaglobulinemia ≤4.5g/l | 38 | 1.28 (0.63–2.62) | 0.49 | ||
| No immunosuppressive treatment | 25 | 0.69 (0.32–1.46) | 0.33 | ||
| No acute GVHD grade ≥2 or treated | 117 | 0.49 (0.27–0.88) | 0.018 | ||
| Bronchiolitis obliterans syndrome | 19 | 1.06 (0.48–2.35) | 0.89 | ||
| Corticosteroid therapy in the prior 30 days | 71 | 2.9 (1.63–5.15) | 0.0003 | ||
| Anti-RSV treatmentb | 45 | 0.89 (0.49–1.6) | 0.69 | ||
| SID score | |||||
| Low (MID) | 15 | 1.00 | |||
| Moderate (SID) | 36 | 1.62 (0.52–5.02) | 0.41 | ||
| High (verySID) | 96 | 1.77 (0.63–4.98) | 0.28 | ||
| ISI | |||||
| Low | 62 | 1.00 | |||
| Moderate | 77 | 1.34 (0.77–2.35) | 0.30 | ||
| High | 8 | 0.27 (0.04–2.02) | 0.20 | ||
CI confidence interval, HSCT haematologic stem cell transplantation, GVHD graft-versus-host disease, RSV respiratory syncytial virus, SID score severe immunodeficiency score, MID moderate immunodeficiency, SID severe immunodeficiency, ISI immunodeficiency scoring index, ALC absolute lymphocyte count, ANC absolute neutrophil count, URTI upper respiratory tract infection, LRTI lower respiratory tract infection.
aat the time of conditionning.
bAll patient received rituximab (10 patients within the three months prior to RSV infection and four patients between four months and six months prior to RSV infection).